Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 7/2011

01.07.2011 | Therapy in Practice

Pharmacological Management of Treatment-Resistant Obsessive-Compulsive Disorder

verfasst von: Anat Abudy, Alzbeta Juven-Wetzler, Prof. Joseph Zohar

Erschienen in: CNS Drugs | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40–60% of patients with OCD. Management of the remaining 40–60% of patients with treatment-resistant OCD is challenging.
We review up-to-date evidence focusing on strategies for treatment-resistant OCD, including increasing the dose of SSRI, switching to another SSRI, augmentation with antipsychotics, and the use of serotonin nor-adrenaline (norepinephrine) reuptake inhibitors (SNRIs) and monoamine oxidase inhibitors (MAOIs). Finally, we provide a flow chart, which includes nonpharmacological interventions such as cognitive-behavioural therapy, family interventions and physical interventions such as neurosurgery and deep brain stimulation, alongside the pharmacological strategies.
Literatur
1.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington,DC: American Psychiatric Association, 2000
2.
Goodman W, Price L, Rasmussen S, et al. The Yale Brown Obsessive Compulsive Scale: validity. Arch Gen Psychiatry 1989; 46: 1012–6PubMedCrossRef
3.
National Collaborating Centre for Mental Health, National Institute for Health and Clinical Excellence. National clinical practice guideline number 31: obsessive compulsive disorder. Core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder. London: The British Psychological Society and The Royal College of Psychiatrists, 2006: 350
4.
Marazziti D, Consoli G. Treatment strategies for obsessive-compulsive disorder. Expert Opin Pharmacother 2010 Feb; 11(3): 331–43PubMedCrossRef
5.
Andrews G, Cremer M, Crino R, et al. The treatment of anxiety disorders: clinician guides and patient manuals. 2nd ed. New York: Cambridge University Press, 2002
6.
Boschen MJ, Drummond LM, Pillay A. Treatment of severe, treatment-refractory obsessive-compulsive disorder: a study of inpatient and community treatment. CNS Spectr 2008 Dec; 13(12): 1056–65PubMed
7.
Geller DA. Obsessive-compulsive and spectrum disorders in children and adolescents. Psychiatr Clin North Am 2006 Jun; 29(2): 353–70PubMedCrossRef
8.
Eisen JL, Mancebo MA, Pinto A, et al. Impact of obsessive compulsive disorder on quality of life. Compr Psychiatry 2006; 47: 270–5PubMedCrossRef
9.
Norberg MM, Calamari JE, Cohen RJ, et al. Quality of life in obsessive compulsive disorder: an evaluation of impairment and preliminary analysis of the ameliorating effects of treatment. Depress Anxiety 2008; 25: 248–59PubMedCrossRef
10.
Olantnji BO, Cisler JM, Toilin DF. Quality of life in the anxiety disorders: a meta-analytic review. Clin Psychol Rev 2007; 27: 572–81CrossRef
11.
Riggs DS, Hiss H, Foa EB. Marital distress and the treatment of obsessive compulsive disorder. Behav Ther 1992; 23: 585–93CrossRef
12.
Leon AC, Portera L, Weissman MM. The social cost of anxiety disorders. Br J Psychiatry Suppl 1995; 27: 19–22PubMed
13.
14.
Pallanti S, Hollander E, Bienstock C,; International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002 Jun; 5(2): 181–91PubMedCrossRef
15.
Jenike MA. Clinical practice: obsessive-compulsive disorder. N Engl J Med 2004 Jan 15; 350(3): 259–65PubMedCrossRef
16.
Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 2004; 65 Suppl. 14: 6–10
17.
Foa EB, Steketee G, Milby JB. Differential effects of exposure and response prevention in obsessive-compulsive washers.J Consult Clin Psychol 1980 Feb; 48(1): 71–9PubMedCrossRef
18.
Franklin ME, Abramowitz JS, Kozak MJ, et al. Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: randomized compared with nonrandomized samples. J Consult Clin Psychol 2000 Aug; 68(4): 594–602PubMedCrossRef
19.
Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005 Jan; 162(1): 151–61PubMedCrossRef
20.
Frost RO, Steketee G. Cognitive approaches to obsessions and compulsions: theory, assessment and treatment. Oxford: Elsevier Science, 2002
21.
Kozak JM, Foa EB. Mastery of obsessive compulsive disorder: a cognitive-behavioral approach. New York: Oxford University Press, 1997
22.
Wilhelm S, Steketee G. Cognitive therapy of obsessive-compulsive disorder: a guide for professionals. Oakland (CA): Harbinger Publications, 2006
23.
Koran LM, Hanna GL, Hollander E, et al., American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007 Jul; 164(7 Suppl. ): 5–53PubMed
24.
Hollander E, Zohar J. Beyond refractory obsessions and anxiety states: toward remission. J Clin Psychiatry 2004; 65 Suppl. 14: 3–5
25.
Fernandez CE, Lopez-Ibor JJ. Mono chlorimipramine in the treatment of psychiatric patients resistant to other therapies. Actas Luso Esp Neurol Psiq Ciec Afines 1967; 26: 119–47
26.
Zohar J, Insel TR. Obsessive-compulsive disorder: psycho-biological approaches to diagnosis, treatment, and patho-physiology. Biol Psychiatry 1987 Jun; 22(6): 667–87PubMedCrossRef
27.
Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder: OCD Paroxetine Study Investigators. Br J Psychiatry 1996 Oct; 169(4): 468–74PubMedCrossRef
28.
Decloedt EH, Stein DJ. Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat 2010 May 25; 6: 233–42PubMedCrossRef
29.
30.
Zohar J. Escitalopram in the treatment of obsessive-compulsive disorder. Expert Rev Neurother 2008 Mar; 8(3): 339–49PubMedCrossRef
31.
Rabinowitz I, Baruch Y, Barak Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2008 Jan; 23(1): 49–53PubMedCrossRef
32.
Ninan PT, Koran LM, Kiev A, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 2006 Jan; 67(1): 15–22PubMedCrossRef
33.
Marazziti D, Golia F, Consoli G, et al. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr 2008 Nov; 13(11): 971–6PubMed
34.
Mundo E, Rouillon F, Figuera ML, et al. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 2001; 16(6): 461–8PubMedCrossRef
35.
Bisserbe J, Lane R, Flament M, the Franco-BelgianOCD Study Group. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 1997; 12(2): 82–93PubMedCrossRef
36.
Stahi SM. Essential psychopharmacology: neuroscientific basis and practical applications. 2nd ed. Cambridge,UK: Cambridge University Press, 2000
37.
Stahl SM. Essential psychopharmacology: neuroscientific basis and practical applications. 2nd ed. Cambridge,UK: Cambridge University Press, 2000
38.
Denys D, van der Wee N, van Megen HJ, et al. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003; 23(6): 568–75PubMedCrossRef
39.
Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996; 57(5): 184–9PubMed
40.
Gürkan K, Bilgiç A, Türkoglu S, et al. Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment. J Psychopharmacol 2010 Dec; 24(12): 1810–8PubMedCrossRef
41.
Vallejo J, Olivares J, Marcos T, et al. Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. Br J Psychiatry 1992 Nov; 161: 665–70PubMedCrossRef
42.
Jenike MA, Baer L, Minichiello WE, et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997 Sep; 154(9): 1261–4PubMed
43.
Fineberg NA, Saxena S, Zohar J, et al. Obsessive-compulsive disorder: boundary issues. CNS Spectr 2007 May; 12(5): 359–64, 367-75PubMed
44.
Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 2004; 65 Suppl. 14: 11–7
45.
Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006 Jul; 11(7): 622–32PubMedCrossRef
46.
McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994 Apr; 51(4): 302–8PubMedCrossRef
47.
Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996 Jul; 57(7): 303–6PubMed
48.
McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000 Aug; 57(8): 794–801PubMedCrossRef
49.
Hollander E, Baldini Rossi N, Sood E, et al. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003 Dec; 6(4): 397–401PubMedCrossRef
50.
D’Amico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2003 Jun; 27(4): 619–23PubMedCrossRef
51.
Bogetto F, Bellino S, Vaschetto P, et al. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000 Oct 30; 96(2): 91–8PubMedCrossRef
52.
Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004 Mar 1; 55(5): 553–5PubMedCrossRef
53.
Denys D, Fineberg N, Carey PD, et al. Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry2007 Feb 1; 61(3): 412–4PubMedCrossRef
54.
Fineberg NA, Stein DJ, Premkumar P, et al. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol 2006 Nov; 21(6): 337–43PubMedCrossRef
55.
Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002 May; 17(3): 115–9PubMedCrossRef
56.
Denys D, de Geus F, van Megen HJ, et al. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004 Aug; 65(8): 1040–8PubMedCrossRef
57.
Fineberg NA, Sivakumaran T, Roberts A, et al. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 2005 Jul; 20(4): 223–6PubMedCrossRef
58.
Mohr N, Vythilingum B, Emsley RA, et al. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 2002 Jan; 17(1): 37–40PubMedCrossRef
59.
Pessina E, Albert U, Bogetto F, et al. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol 2009 Sep; 24(5): 265–9PubMedCrossRef
60.
Metin O, Yazici K, Tot S, et al. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 2003 Aug; 18(6): 463–7PubMedCrossRef
61.
March JS, Franklin ME, Leonard H, et al. Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 2007 Feb 1; 61(3): 344–7PubMedCrossRef
62.
Matsunaga H, Nagata T, Hayashida K, et al. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009 Jun; 70(6): 863–8PubMedCrossRef
63.
McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991 Jun; 11(3): 175–84PubMedCrossRef
64.
Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007 Jun; 27(3): 263–72PubMedCrossRef
65.
McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993 Apr; 150(4): 647–9PubMed
66.
Barr LC, Goodman WK, Anand A, et al. Addition of desi-pramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 1997 Sep; 154(9): 1293–5PubMed
67.
Stahl SM. Essential psychopharmacology, neuroscientific basis and practical applications. 3rd ed. San Diego (CA): Cambridge University Press, 2008
68.
Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 2004 Oct; 65(10): 1394–9PubMedCrossRef
69.
Koran LM, Gamel NN, Choung HW, et al. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 2005 Apr; 66(4): 515–20PubMedCrossRef
70.
Diniz JB, Shavitt RG, Pereira CA, et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J Psychopharmacol 2010 Mar; 24(3): 297–307PubMedCrossRef
71.
Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet 2009 Aug 8; 374(9688): 491–9PubMedCrossRef
72.
Figee M, Denys D. New pharmacotherapeutic approaches to obsessive-compulsive disorder. CNS Spectr 2009 Feb; 14(2 Suppl. 3): 13–23PubMed
73.
Van Ameringen M, Mancini C, Patterson B, et al. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 2006; 23(1): 1–5PubMedCrossRef
74.
Coric V, Milanovic S, Wasylink S, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003 May; 167(2): 219–20
75.
Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 2009 Feb; 29(1): 51–5PubMedCrossRef
76.
Stewart SE, Jenike EA, Hezel DM, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 2010 Feb; 30(1): 34–9PubMedCrossRef
77.
Feusner JD, Kerwin L, Saxena S et al. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull 2009; 42(1): 81–93
78.
Hewlett WA, Schmid SP, Salomon RM. Pilot trial of on-dansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry 2003 Sep; 64(9): 1025–30PubMedCrossRef
79.
Pallanti S, Bernardi S, Antonini S, et al. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 2009 Dec 1; 23(12): 1047–55PubMedCrossRef
80.
Lundberg S, Carlsson A, Norfeldt P, et al. Nicotine treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004 Nov; 28(7): 1195–9PubMedCrossRef
81.
Taylor LH, Kobak KA. An open-label trial of St. John’s wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000 Aug; 61(8): 575–8
82.
Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992 Dec; 12(6): 420–30PubMedCrossRef
83.
Crockett BA, Churchill E, Davidson JR. A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry 2004 Jul–Sep; 16(3): 127–32PubMedCrossRef
84.
Pigott TA, L’Heureux F, Rubenstein CS, et al. A doubleblind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992 Jun; 12(3): 156–62PubMedCrossRef
85.
Insel TR, Hamilton JA, Guttmacher LB, et al. D-amphetamine in obsessive-compulsive disorder. Psychopharmacology (Berl) 1983; 80(3): 231–5CrossRef
86.
Joffe RT, Swinson RP, Levitt AJ. Acute psychostimulant challenge in primary obsessive-compulsive disorder. J Clin Psychopharmacol 1991 Aug; 11(4): 237–41PubMedCrossRef
87.
Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2009 Nov; 70(11): 1530–5PubMedCrossRef
88.
Amiaz R, Fostick L, Gershon A, et al. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol 2008 Jun; 18(6): 455–61PubMedCrossRef
89.
Dannon PN, Sasson Y, Hirschmann S, et al. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000 May; 10(3): 165–9PubMedCrossRef
90.
Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998 Sep; 13(5): 219–24PubMedCrossRef
91.
Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmacol 1999 Sep; 2(3): 193–5PubMedCrossRef
92.
Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 2002 Sep; 63(9): 796–801PubMedCrossRef
93.
Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997 Mar; 154(3): 396–401PubMed
94.
Koran LM, Pallanti S, Paiva RS, et al. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. Eur Neuropsychopharmacol 1998 May; 8(2): 121–6PubMedCrossRef
95.
Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 1998 Oct; 55(10): 918–24PubMedCrossRef
96.
Koran LM, Aboujaoude E, Ward H, et al. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2006 Feb; 26(1): 79–83PubMedCrossRef
97.
Vulink NC, Denys D, Fluitman SB, et al. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry 2009 Jul; 70(7): 1001–8PubMedCrossRef
Metadaten
Titel
Pharmacological Management of Treatment-Resistant Obsessive-Compulsive Disorder
verfasst von
Anat Abudy
Alzbeta Juven-Wetzler
Prof. Joseph Zohar
Publikationsdatum
01.07.2011
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 7/2011
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11587860-000000000-00000

Weitere Artikel der Ausgabe 7/2011

CNS Drugs 7/2011 Zur Ausgabe

Review Article

Issues in the Management of Challenging Behaviours of Adults with Autism Spectrum Disorder

Adis Drug Profile

Vilazodone

Leading Article

Enhancing CNS Repair in Neurological Disease

Leading Article

Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder

Short Communication

Rituximab for Secondary Progressive Multiple Sclerosis

Therapy in Practice

Transdermal Rivastigmine

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise